Predicted STAT1-BRAF and IRF7-MET Regulatory Links Are Associated with MAPK Pathway Reactivation and Targeted Therapy Resistance in Melanoma
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188031 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Hao Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, Institute of Precision Medicine, School of Medical Technology and Engi…. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm, STAT1 Transcription Factor. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Science and Technology Innovation Joint Fund Project.
Abstract (Originalsprache)
Resistance to BRAF inhibitors (BRAFi), alone or with MEK inhibitors (MEKi), limits durable responses in BRAF-mutant melanoma. To characterize resistance-associated cell-state evolution, we analyzed 674 melanoma cells from six mice bearing tumors from a single patient-derived BRAF V600E-mutant melanoma xenograft (PDX) lineage before treatment, during initial regression, at minimal residual disease, and at resistant regrowth. Unsupervised clustering based on a BRAF-centered network feature set comprising 2506 candidate genes identified six transcriptional states, which were characterized using transcriptomic analyses. Cluster 4 was detected exclusively at resistant regrowth, a phase marked by MAPK pathway reactivation, and exhibited enhanced JAK-STAT/interferon signaling and increased STAT1, STAT2, IRF7, IRF9, and RELB regulon activities. Network inference predicted STAT1-BRAF and IRF7-MET regulatory links, suggesting candidate routes to MAPK reactivation through BRAF overexpression and MET-mediated bypass signaling. External analyses partially recapitulated the resistance-associated transcriptional program in independent melanoma cell-line datasets and yielded limited, inconclusive evidence for the predicted STAT1-BRAF association in public perturbation datasets. Cluster 2 represented a pre-existing proliferative state whose signature was associated with shorter progression-free survival in pretreatment clinical cohorts. Together, these findings distinguish a therapy-associated acquired-resistance state from a pre-existing proliferative resistance-associated state and nominate the predicted STAT1-BRAF and IRF7-MET links for functional validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, Institute of Precision Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China.
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350122, China.
ORCID-Profile: Hao Fu, Xiaopei Shen, Jun He
Förderung
- Fujian Science and Technology Innovation Joint Fund Project
Zitieren
APA
Fu, H., Wang, M., Zhu, H., Li, W., Shen, X., Yan, H., & He, J. (2026). Predicted STAT1-BRAF and IRF7-MET Regulatory Links Are Associated with MAPK Pathway Reactivation and Targeted Therapy Resistance in Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188031
Vancouver
Fu H, Wang M, Zhu H, Li W, Shen X, Yan H, et al. Predicted STAT1-BRAF and IRF7-MET Regulatory Links Are Associated with MAPK Pathway Reactivation and Targeted Therapy Resistance in Melanoma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188031
BibTeX
@article{Fu2026,
author = {Fu, Hao and Wang, Mengyao and Zhu, Haibo and Li, Weihua and Shen, Xiaopei and Yan, Haidan and He, Jun},
title = {Predicted STAT1-BRAF and IRF7-MET Regulatory Links Are Associated with MAPK Pathway Reactivation and Targeted Therapy Resistance in Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188031}
}
EUVIMED